As the Founding Editor-in-Chief of the Journal of Thrombosis and Thrombolysis, which is approaching its 20th year of publication, I often reflect on a fundamental question, ''What makes a great medical journal''? A great medical journal must be true to its mission. In the case of the Journal of Thrombosis and Thrombolysis, we pledged to focus our attention on the pathobiology of thrombosis and vascular disorders involving the cardiovascular and cerebrovascular circulatory systems, the development, study and use of anticoagulants, platelet antagonists, hybrid antithrombotic strategies, fibrinolytics, cell-based therapies and interventions that could be translated, through high quality scientific investigation to the betterment of patient care. We further pledged to publish original work that emphasized the interface between fundamental scientific principles and clinical investigation, stimulating an interdisciplinary and scholarly dialogue among clinicians of varied backgrounds.
To successfully achieve our goal, we assembled a worldclass team of thought leaders in the academic community to serve as associate editors and section editors for the Journal. We now recognize one of our associate editors, Harold Dauerman, M.D., who has stepped down from his position to serve as the Editor-in-Chief of Coronary Artery Disease. During his near 10-year tenure of service to the Journal of Thrombosis and Thrombolysis, Dr. Dauerman has been a constant source of motivation, innovation and inspiration, consistently offering clear vision, diplomacy, tireless and uncompromising commitment to excellence and to ''reaching our readership'' through contemporary, yet pragmatic publications.
On behalf of the Journal I will extend my heart-felt thanks to Dr. Dauerman for his countless contributions and wish him success in his future scholarly endeavors.
